Danaher raised its annual profit forecast on Tuesday, signaling earnings strength, but trimmed its core revenue growth outlook and posted weaker-than-expected biotechnology revenue, triggering roughly a 12% premarket drop. The divergence between stronger profitability and slower top-line growth suggests near-term stock pressure despite solid margins, with outcome hinges on biotech momentum and potential for guidance revision if conditions improve.
Danaher reported a solid Q2 with revenue at $6.3B and net earnings of $870M ($1.23 per share), up 60% YoY, along with an 8% rise in non-GAAP EPS to $1.94. Core revenue rose 3.0% (4.5% excluding respiratory testing), and operating cash flow was $1.5B. The Masimo acquisition has closed earlier than expected, enabling a higher full-year EPS target of $8.45–$8.60, while the company also updates guidance for 3Q and full-year core sales growth. A new non-GAAP metric, core sales excluding respiratory testing, was introduced to better reflect underlying growth, and tariff refunds will be excluded from core starting in Q3 2026.
Danaher Corporation has priced a €2.98 billion senior notes offering to finance its acquisition of Masimo Corporation. This capital raise could strengthen Danaher's balance sheet and accelerate its strategic growth in the life sciences sector.
Danaher Corporation reported solid Q1 2026 results, with net earnings of $1.0 billion and a 9.5% increase in adjusted EPS to $2.06. The company also raised its full-year EPS guidance to $8.35-$8.55, and announced an acquisition of Masimo Corporation, expected to enhance its healthcare offerings.
Danaher Corporation reported solid Q1 2026 results with a 9.5% growth in non-GAAP adjusted earnings per share and a 3.5% increase in revenue to $6 billion. The company also announced plans to acquire Masimo, which may further enhance its capabilities in health technology and diagnostics.
Danaher's acquisition of Masimo for $9.9 billion aims to enhance its diagnostics segment while allowing Masimo to operate independently. This strategic move could elevate Danaher's market position and growth potential in the healthcare sector, potentially providing long-term benefits to investors.
